Signs Agreement with Global Healthcare Company
ROUSES POINT, N.Y., Jan. 6 /PRNewswire/ -- Akrimax Pharmaceuticals, LLC announced today a manufacturing agreement for the production of pharmaceutical products for a global company beginning in 2009. Akrimax was selected from several potential partners in a competitive process.
Akrimax President Alan L. Rubino said: "This agreement further validates Akrimax's decision to acquire the Rouses Point facility which possesses diverse manufacturing and packaging capabilities, and a spotless regulatory and safety record. We are pleased to announce this development as we are ahead of our planned schedule of bringing in new manufacturing partnerships to our Rouses Point facility."
Rubino also said: "Our contract manufacturing partnership enhances our strategic plan and showcases the quality of our people and our ability to execute at this facility. We are proving every day that Made in America pharmaceutical manufacturing is good business for our partners because of our high-quality manufacturing, competitive value and excellent track record with the FDA."
Akrimax Pharmaceuticals, LLC is a privately-held, fully-integrated next-generation specialty pharmaceutical company concentrated on acquiring marketed products and developing select late-stage products to address disease states related to "metabolic syndrome." The company also owns a world-class plant in Rouses Point, NY with a highly skilled workforce. Akrimax manufactures its own products and develops select manufacturing partnerships. The plant encompasses 67.6 acres with 38 buildings, offering approximately 1 million sq. feet of manufacturing and packaging space. Akrimax was formed in 2007 and purchased the Rouses Point plant from Wyeth in January 2008.
Based in Cranford, NJ, Akrimax pursues unsurpassed quality in the development, production, manufacturing, distribution, and commercialization of a full range of top-quality pharmaceutical products. Akrimax currently markets Inderal(R) LA and LoOvral(R) branded products and operates the manufacturing facility in conjunction with Wyeth during a transition period that runs through 2009. www.Akrimax.com
CONTACT: Timothy Soule of Akrimax Pharmaceuticals, LLC,
email@example.com; or Kevin Ellis of Kimbell Sherman Ellis for Akrimax
Pharmaceuticals, LLC, +1-800-498-5390, ext. 107, Kevin@kse50.com
Web site: http://www.Akrimax.com/